Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis

JAMA

Volumn 299, Issue 1, 2008, Pages 53-60

  Tanabe, Kenneth K ^a,e   Lemoine, Antoinette ^b   Finkelstein, Dianne M ^a   Kawasaki, Hiroshi ^a   Fujii, Tsutomu ^a   Chung, Raymond T ^a   Lauwers, Gregory Y ^a   Kulu, Yakup ^a   Muzikansky, Alona ^a   Kuruppu, Darshini ^a   Lanuti, Michael ^a   Goodwin, Jonathan M ^a   Azoulay, Daniel ^b,c,d   Fuchs, Bryan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSERM   (France)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; ALLELE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 38049059334     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2007.65     Document Type: Article

References (33)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118(12):3030-3044.
2. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23(13):2892-2899.
3. IARC. Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 59. Lyon, France: International Agency for Research on Cancer; 2004.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2): 74-108.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917.
6. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-1562.
7. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216.
8. Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev. 1990;11(3):418-442.
9. Blanc P, Etienne H, Daujat M, et al. Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum. Gastroenterology. 1992;102(4 pt 1):1340-1350.
10. Hoffmann B, Piasecki A, Paul D. Proliferation of fetal rat hepatocytes in response to growth factors and hormones in primary culture. J Cell Physiol. 1989;139(3):654-662.
11. Mullhaupt B, Feren A, Fodor E, Jones A. Liver expression of epidermal growth factor RNA: rapid increases in immediate-early phase of liver regeneration. J Biol Chem. 1994;269(31):19667-19670.
12. Stoscheck CM, King LE Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res. 1986;46(3):1030-1037.
13. Roberts AB, Roche NS, Sporn MB. Selective inhibition of the anchorage-independent growth of myctransfected fibroblasts by retinoic acid. Nature. 1985;315(6016):237-239.
14. Singletary SE, Baker FL, Spitzer G, et al. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res. 1987;47(2):403-406.
15. Stern DF, Hare DL, Cecchini MA, Weinberg RA. Construction of a novel oncogene based on synthetic sequences encoding epidermal growth factor. Science. 1987;235(4786):321-324.
16. Tönjes RR, Lohler J, O'Sullivan JF, et al. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene. 1995;10(4):765-768.
17. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene. 2005;24(11):1809-1819.
18. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359(9304):397-401.
19. Park JG, Lee JH, Kang MS, et al. Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer. 1995;62(3):276-282.
20. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector [published correction appears in Ann Surg. 1998;228(5):followi(ng)]. Ann Surg. 1998;228(3):366-374.
21. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 2000;14(2):301-311.
22. Ding C, Maier E, Roscher AA, Braun A, Cantor CR. Simultaneous quantitative and allele-specific expression analysis with real competitive PCR. BMC Genet. 2004;5:8.
23. Oka Y, Orth DN. Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets. J Clin Invest. 1983;72(1):249-259.
24. Saffroy R, Pham P, Chiappini F, et al. The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis. 2004;25(8):1443-1448.
25. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e313.
26. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985;1(8425):364-366.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
28. Kömüves LG, Feren A, Jones AL, Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem. 2000;48(6):821-830.
29. Berrahmoune H, Herbeth B, Lamont JV, Masson C, Fitzgerald SP, Visvikis-Siest S. Lack of association between EGF 61A>G Polymorphism and Plasma EGF Concentration in the STANISLAS Family Study. J Invest Dermatol. 2007;127(4):969-970.
30. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64(4):1220-1223.
31. Amend KL, Elder JT, Tomsho LP, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res. 2004;64(8):2668-2672.
32. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. N Engl J Med. 1998;338(2):122-124.
33. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41(2):307-314.